Corbus Pharma's Positive Phase 2 Study: Safety First By: Benzinga via Benzinga March 30, 2017 at 14:56 PM EDT Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) has received a price target increase to $24 from $17 from Cantor Fitzgerald, which ... Read More >> Related Stocks: Corbus Pharmaceuticals Hldgs Inc Vertex Pharmaceuticals